CD274 and cancer: Several therapeutic antibodies targeting PD-L1 (e.g., atezolizumab, avelumab, durvalumab) and PD-1 (e.g., nivolumab, pembrolizumab, cemiplimab) are administered in clinical practice in various cancer types.